Supply-Chain Transparency and Country-of-Origin Readiness

A medical device may be clinically suitable, FDA-authorized, and commercially available yet still be difficult to offer to a federal customer if the manufacturer cannot explain where it is made, how origin was determined, who supplied key components, and how authenticity and continuity are controlled.

Country of Origin Is Not a Single Universal Conclusion

Country of origin is not a single universal conclusion. Customs marking, the Buy American statute, the Trade Agreements Act, agency-specific rules, and the solicitation may apply different definitions or tests.

Under some Trade Agreements Act clauses, the question may be whether the offered end product was wholly produced or substantially transformed in the United States or a designated country. Buy American analysis may instead examine U.S. manufacture and domestic component content.

A “Made in” label, customs entry, or supplier certificate does not automatically resolve every federal procurement representation.

Build the Record Before the Solicitation

The manufacturer should maintain a product-origin file identifying the legal manufacturer, manufacturing and assembly locations, significant processing steps, bill of materials, and rationale for any substantial-transformation conclusion.

The file should distinguish the finished device from accessories, kits, spare parts, software, and separately offered consumables because different line items may have different origins.

Supply-Chain Readiness Requires Visibility Below Final Assembly

Supply-chain readiness also requires visibility below final assembly. Critical components should be identified based on safety, performance, availability, cybersecurity, and replacement risk.

Approved-supplier records should show who is authorized to manufacture or distribute them, how changes are controlled, and what supports authenticity.

For products containing electronic parts, some Department of Defense requirements may impose additional expectations for authorized sources, traceability, testing, quarantine, reporting, and counterfeit avoidance.

Traceability Should Connect the Entire Product Lifecycle

Traceability should connect incoming components, production lots, serial numbers, released devices, authorized distributors, federal orders, deliveries, repairs, returns, and replacements.

This helps demonstrate that the product offered is the product delivered and reduces the risk of grey-market, diverted, altered, or counterfeit units entering the channel.

Cybersecurity and Continuity Are Supply-Chain Issues

Connected and software-enabled products depend on more than physical components. Firmware, software libraries, cloud services, mobile applications, remote-support tools, update servers, telecommunications modules, and third-party providers may affect security and continued operation.

The manufacturer should know which dependencies are essential, who controls them, how vulnerabilities and updates are managed, and what happens if a supplier or service becomes unavailable.

Continuity Planning Should Match the Federal Offer

Continuity planning should address alternate approved sources, component obsolescence, safety stock, lead times, repair capacity, substitute-part validation, disaster recovery, and customer notification.

These plans should align with the product configuration and delivery commitments represented in the offer.